The most common adverse effects observed in clinical trials were [[upper respiratory tract infection]]s (more than 10% of patients), [[nasopharyngitis]] (common cold), headache, and high blood pressure (at least 5%). The enzyme [[alanine transaminase]] was also elevated in at least 5% of patients, but in most cases without symptoms. Elevated total cholesterol levels were common.<ref>{{Cite journal | last1 = Genovese | first1 = M. C. | last2 = McKay | first2 = J. D. | last3 = Nasonov | first3 = E. L. | last4 = Mysler | first4 = E. F. | last5 = Da Silva | first5 = N. A. | last6 = Alecock | first6 = E. | last7 = Woodworth | first7 = T. | last8 = Gomez-Reino | first8 = J. J. | doi = 10.1002/art.23940 | title = Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study | journal = Arthritis & Rheumatism | volume = 58 | issue = 10 | pages = 2968â€“80 | year = 2008 | pmid = 18821691| pmc = }}</ref>  Among the less common side effects were dizziness, various infections, as well as reactions of the skin and [[mucosae]] like mild rashes, [[gastritis]] and [[mouth ulcer]]. Rare but severe reactions were [[gastrointestinal perforation]]s (0.26% in six months) and [[anaphylaxis]] (0.2%).<ref name="Arzneistoff-Profile" />

 

